Alector (ALEC) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and technology platform

• Focuses on neurodegeneration with a portfolio of antibodies, enzymes, and nucleic acid therapeutics leveraging proprietary blood-brain barrier technology.

• Uses a transferrin receptor-based platform as a 'Trojan horse' to deliver drugs across the blood-brain barrier, with unique epitope selection to maximize brain penetration and minimize anemia risk.

• Platform is tunable for different drug modalities, optimizing affinity and safety for each therapeutic.

• Proprietary epitope enables high potency and safety, allowing delivery of antibodies, enzymes, and nucleic acids to the brain.

Lead programs and clinical milestones

• Lead candidate AL137, an anti-Aβ antibody, is set to enter the clinic by April next year, designed for monthly subcutaneous delivery.

• AL137 targets the pyroglutamate epitope on Aβ, aiming for superior efficacy and safety compared to first, second, and third-generation anti-Aβ antibodies.

• Phase I study in Australia will test four subcutaneous dose cohorts, followed by a phase I-B MAD study in Alzheimer's patients in the U.S. with monthly dosing and biomarker/imaging endpoints.

• Key gating factor for clinical initiation is completion of manufacturing; data will be reported on an ongoing basis.

Preclinical and clinical data insights

• Preclinical studies show AL137 achieves several-fold higher brain exposure than competitors at lower peripheral doses, with a safer hematological profile.

• Subcutaneous delivery reduces Cmax and peripheral adverse effects while maintaining high brain exposure.

• Non-human primate studies show no significant reduction in red blood cells or hemoglobin with the masked epitope, supporting a favorable safety profile.

• Phase I-B will monitor Aβ plaque reduction, p-tau217, anemia, infusion reactions, and ARIA rates, with PET imaging and biomarker analysis.